• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

依普利酮通过抑制内皮细胞中的盐皮质激素受体改善肺血管重塑和高血压。

Eplerenone Improves Pulmonary Vascular Remodeling and Hypertension by Inhibition of the Mineralocorticoid Receptor in Endothelial Cells.

作者信息

Kowalski Jessica, Deng Lisa, Suennen Chiara, Koca Duygu, Meral David, Bode Christoph, Hein Lutz, Lother Achim

机构信息

From the Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine (J.K., L.D., C.S., D.K., D.M., L.H., A.L.), University of Freiburg, Germany.

Spemann Graduate School of Biology and Medicine (SGBM), Cardiovascular Research Track (D.M.), University of Freiburg, Germany.

出版信息

Hypertension. 2021 Aug;78(2):456-465. doi: 10.1161/HYPERTENSIONAHA.120.16196. Epub 2021 May 10.

DOI:10.1161/HYPERTENSIONAHA.120.16196
PMID:33966455
Abstract

[Figure: see text].

摘要

[图：见正文]。

相似文献

1
Eplerenone Improves Pulmonary Vascular Remodeling and Hypertension by Inhibition of the Mineralocorticoid Receptor in Endothelial Cells.依普利酮通过抑制内皮细胞中的盐皮质激素受体改善肺血管重塑和高血压。
Hypertension. 2021 Aug;78(2):456-465. doi: 10.1161/HYPERTENSIONAHA.120.16196. Epub 2021 May 10.
2
Mineralocorticoid receptor antagonism improves parenchymal arteriole dilation via a TRPV4-dependent mechanism and prevents cognitive dysfunction in hypertension.醛固酮受体拮抗作用通过 TRPV4 依赖机制改善实质小动脉扩张，并预防高血压认知功能障碍。
Am J Physiol Heart Circ Physiol. 2018 Nov 1;315(5):H1304-H1315. doi: 10.1152/ajpheart.00207.2018. Epub 2018 Aug 17.
3
Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice.直接肾素抑制对血管紧张素 II 依赖性高血压小鼠中盐皮质激素受体阻断的影响。
Hypertens Res. 2020 Oct;43(10):1099-1104. doi: 10.1038/s41440-020-0458-5. Epub 2020 May 12.
4
Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension.依普利酮可减轻肺动脉高压中的病理性肺血管重构而非右心室重构。
BMC Pulm Med. 2018 Mar 2;18(1):41. doi: 10.1186/s12890-018-0604-x.
5
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.新型高效选择性非甾体盐皮质激素受体拮抗剂CS-3150的药理学特性
Eur J Pharmacol. 2015 Aug 15;761:226-34. doi: 10.1016/j.ejphar.2015.06.015. Epub 2015 Jun 11.
6
Regulation of myogenic tone and structure of parenchymal arterioles by hypertension and the mineralocorticoid receptor.高血压和盐皮质激素受体对实质小动脉肌源性张力和结构的调节
Am J Physiol Heart Circ Physiol. 2015 Jul 1;309(1):H127-36. doi: 10.1152/ajpheart.00168.2015. Epub 2015 Apr 24.
7
Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling.螺内酯诱导的 TFIIH 核心复合物 XPB 亚基降解抑制 NF-κB 和 AP-1 信号通路。
Cardiovasc Res. 2018 Jan 1;114(1):65-76. doi: 10.1093/cvr/cvx198.
8
Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.盐皮质激素受体阻断和钙通道阻断对大鼠肾小球和间质损伤具有不同的肾脏保护作用。
Am J Physiol Renal Physiol. 2009 Sep;297(3):F802-8. doi: 10.1152/ajprenal.00197.2009. Epub 2009 Jun 17.
9
Mineralocorticoid receptor antagonists and endothelial function.盐皮质激素受体拮抗剂与内皮功能
Curr Opin Investig Drugs. 2008 Sep;9(9):963-9.
10
Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR/proteoglycan/TLR4 pathway.盐皮质激素受体（MR）拮抗剂依普利酮和MR调节剂巴尔西雷酮通过MR/蛋白聚糖/TLR4途径预防肾脏细胞外基质重塑和炎症。
Clin Sci (Lond). 2024 Aug 21;138(16):1025-1038. doi: 10.1042/CS20240302.

引用本文的文献

1
Mineralocorticoid receptor antagonists promote renal immunosenescence.盐皮质激素受体拮抗剂会促进肾脏免疫衰老。
Int Urol Nephrol. 2025 Apr 30. doi: 10.1007/s11255-025-04530-1.
2
Suppressing the expression of steroidogenic acute regulatory protein (StAR) in the myocardium by spironolactone contributes to the improvement of right ventricular remodeling in pulmonary arterial hypertension.螺内酯抑制心肌中类固醇生成急性调节蛋白（StAR）的表达有助于改善肺动脉高压患者的右心室重塑。
Hypertens Res. 2024 Dec;47(12):3423-3433. doi: 10.1038/s41440-024-01908-z. Epub 2024 Oct 4.
3
Mineralocorticoid Receptors in Vascular Smooth Muscle: Blood Pressure and Beyond.
血管平滑肌中的盐皮质激素受体：血压与超越血压。
Hypertension. 2024 May;81(5):1008-1020. doi: 10.1161/HYPERTENSIONAHA.123.21358. Epub 2024 Mar 1.
4
The influence of steroid type on outcomes in patients with acute respiratory distress syndrome.类固醇类型对急性呼吸窘迫综合征患者预后的影响。
J Intensive Care. 2023 Jul 10;11(1):32. doi: 10.1186/s40560-023-00681-4.
5
Finerenone: Questions and Answers-The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist.非奈利酮：问答——关于新型有前景的非甾体盐皮质激素受体拮抗剂的四大基本论点
J Clin Med. 2023 Jun 12;12(12):3992. doi: 10.3390/jcm12123992.
6
Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research.肺动脉高压中盐皮质激素受体的治疗靶点：基础研究的见解
Front Cardiovasc Med. 2023 Jan 30;10:1118516. doi: 10.3389/fcvm.2023.1118516. eCollection 2023.
7
Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy.非奈利酮，一种非甾体盐皮质激素受体拮抗剂，可减少血管损伤并增加调节性 T 细胞：在糖尿病和新生血管性视网膜病变的啮齿动物中的研究。
Int J Mol Sci. 2023 Jan 25;24(3):2334. doi: 10.3390/ijms24032334.
8
Emerging vascular cell-specific roles for mineralocorticoid receptor: implications for understanding sex differences in cardiovascular disease.醛固酮受体在血管细胞中出现的新作用：对理解心血管疾病中性别差异的意义。
Am J Physiol Cell Physiol. 2023 Jan 1;324(1):C193-C204. doi: 10.1152/ajpcell.00372.2022. Epub 2022 Nov 28.
9
Profibrotic Effects of Endothelin-1 on Fibroblasts Are Mediated by Aldosterone in Vitro: Relevance to the Pathogenesis and Therapy of Systemic Sclerosis and Pulmonary Arterial Hypertension.内皮素-1对成纤维细胞的促纤维化作用在体外由醛固酮介导：与系统性硬化症和肺动脉高压的发病机制及治疗的相关性
Biomedicines. 2022 Oct 31;10(11):2765. doi: 10.3390/biomedicines10112765.
10
Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms.盐皮质激素受体激活与拮抗在心血管疾病中的作用：细胞与分子机制
Kidney Int Suppl (2011). 2022 Apr;12(1):19-26. doi: 10.1016/j.kisu.2021.11.001. Epub 2022 Mar 18.